Although biosimilars have been part of clinical practice for more than a decade, healthcare
professionals (HCPs) do not fully accept them. This is because of the perception that …

Abstract Background and Objective While biosimilars are less expensive than their
originator biologics, various factors are known to impede their uptake in clinical practice …

Objective: With increasing numbers of biosimilars entering the market or in the approval
pipeline in China, understanding the current awareness and attitudes of biosimilars still …

Aims. Pharmacists in all clinical settings are recognized drug experts and integral educators
of biosimilar medicines. Therefore, the objective of this study was to assess pharmacists' …

Background Biosimilars can improve patient access to biological medicines. Although
biosimilars have been shown to be equally effective and safe, some patients remain …

The study objectives were to 1) explore the real-world experience of hospital pharmacists
with the differences in effectiveness safety, and interchangeability between biosimilar …

Background: The aim of the present study was to understand hospital pharmacists' views
and practices regarding generic substitution and therapeutic interchange. Method: This was …

Abstract Background and Objective Biosimilars represent an opportunity to realise savings
against the costs of innovative medicines. Despite efforts made by stakeholders, there are …

Background Knowledge, attitudes and substitution laws of biosimilars are not consistent
across countries. Biosimilar acceptance among patients and healthcare professionals may …

Background Biopharmaceutical medicines have transformed the treatment of various long-
term diseases, despite their high cost and limited availability. Due to their cost saving …